Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 16/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863961 | 1.00 | DPP4 (0.42) | DPP4DPP7DPP9DPP8KCNH2 | |
| SCHEMBL864493 | 0.85 | DPP4 (0.46) | DPP4DPP7DPP9DPP8KCNH2 | |
| SCHEMBL864492 | 0.85 | DPP4 (0.46) | DPP4DPP7DPP9DPP8KCNH2 | |
| SCHEMBL16379880 | 0.83 | CTSK (0.43) | — | |
| SCHEMBL21468963 | 0.83 | CTSK (0.43) | — | |
| SCHEMBL5373342 | 0.82 | DPP4 (0.50) | DPP4DPP7DPP9DPP8KCNH2 | |
| SCHEMBL21469066 | 0.80 | KMT2A (0.36) | NPC1ALDH1A1MAPTMAPK1HTT | |
| SCHEMBL17776401 | 0.80 | LIPC (0.39) | ALDH1A1 | |
| SCHEMBL16379822 | 0.80 | LIPC (0.39) | ALDH1A1 | |
| SCHEMBL16379872 | 0.80 | LIPG (0.34) | NPC1ALDH1A1MAPTMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-29 | — | — | US | disclosed |
| EP-2406247-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010103333-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, GPR132, FFAR2 | DPP4 217/4885DPP7 276/4885DPP9 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.